Aberrant SEPT9 methylation was the biomarker targeted by Epi proColon 2.0 test, a FDA-approved CRC screening assay detecting methylated SEPT9 (mSEPT9) in blood [10, 11]. Here, SEPTIN9 is linked to colorectal carcinoma.